Search results
2 new COVID variants called 'FLiRT' are spreading in the U.S. What are the symptoms?
TODAY via Yahoo News· 1 day agoThe new "FLiRT" COVID-19 variants, including KP.2, are spreading in the United States. Will there be...
Want To Avoid Food Poisoning? Skip These Items At Your Hotel's Breakfast Buffet
HuffPost Life via Yahoo News· 2 days agoAs for juices, both fresh and pasteurized should be cold. Since fresh juice isn’t pasteurized,...
The 26th Annual Food Safety Summit Attracts 3,400 Food Safety Professionals In Person and Virtually,...
Morningstar· 1 day agofood safety industry professionals, researchers, policymakers, and experts from around the world participated in the 2024 Food Safety ...
...Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men...
WKRN Nashville· 2 days agoSumitomo Pharma America, Inc. (SMPA), announced today the U.S. Food and Drug Administration (FDA) has accepted its ...
Nut recall as "life-threatening" warning issued
Newsweek· 6 days agoA nut recall was issued this week alongside warnings of a possible "life-threatening" allergic reaction. On Wednesday, the U.S. Food and Drug< ...
How incentives could better treat stimulant use disorder
Medical Xpress· 5 days agoAlthough research has been underway for more than three decades to develop medications for people...
PhALLCON Soars to New Heights—Faster, Stronger, but Better?
Journal of the American Medical Association· 6 days agoIn this issue of JAMA, Jabbour and colleagues1 report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with reduced-intensity ...
Altimmune Inc (ALT) Reports Q1 2024 Financials: A Detailed Review
GuruFocus.com via Yahoo Finance· 4 days agoThe company is preparing for an End-of-Phase 2 meeting with the U.S. Food and Drug Administration...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter...
Morningstar· 2 days ago― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report ...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
WRBL Columbus· 10 hours agoExpanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors Generated ...